Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial

Minesh Mehta

Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial

Minesh Mehta

Herbert Wertheim Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	JAMA Oncology
Volume	4
State	Published - Oct 1 2018

Access to Document

ViewcontentFinal published version, 20.4 KBLicense: Unspecified

Cite this

@article{cfd00b07b46a4125bc6e3c7429941954,

title = "Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial",

author = "Minesh Mehta",

note = "JAMA Oncol (2018) 4(10):1405-1409",

year = "2018",

month = oct,

day = "1",

language = "American English",

volume = "4",

journal = "JAMA Oncology",

}

TY - JOUR

T1 - Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial

AU - Mehta, Minesh

N1 - JAMA Oncol (2018) 4(10):1405-1409

PY - 2018/10/1

Y1 - 2018/10/1

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/2844

M3 - Article

VL - 4

JO - JAMA Oncology

JF - JAMA Oncology

ER -

Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial

Access to Document

Other files and links

Cite this